Glaxo expects better profit after good sales of shingles vaccine
CEO Emma Walmsley has embarked on a plan to rejuvenate Glaxo, which has included the spin off or sale of some units since she took over in 2017
30 October 2019 - 17:30
Bengaluru — GlaxoSmithKline on Wednesday raised its annual profit forecast for the second time in 2019 as sales of its shingles vaccine beat expectations and older medicines, including HIV/AIDS treatments, continued to sell well.
The British drugmaker’s shares rose as much as 3% to a more than a six-year high after the company said it now expected profit to be roughly flat at constant currency for the year, compared with a previous forecast of a fall of 3%-5%...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.